Skip to content

Management of Myopia in University Students With DIMS-TED Spectacle Lenses

Management of Myopia in University Students Using Defocus Incorporated Multiple Segment (DIMS) Spectacle Lenses.

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07679477
Acronym
MoMUS-DIMS
Enrollment
38
Registered
2026-07-01
Start date
2025-10-01
Completion date
2029-10-01
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia Progression

Brief summary

The purpose of the study is to quantify the effectiveness of Hoya MiyoSmart IQ (DIMS-TED) spectacle lenses in slowing the rate of myopia progression in university students.

Detailed description

MiyoSmart spectacle lenses have been shown to be a safe and effective way of managing myopia progression in children aged 8-12 years. However, myopic progression is not limited to children of this age group and there is evidence that progression also occurs in university students. The researchers are therefore investigating the effectiveness of this intervention in a group of UK-based University students.

Interventions

DEVICEDIMS TED spectacle lenses

Spectacle lenses for myopia management

Single vision spectacle lenses as control

Sponsors

University of Bradford
Lead SponsorOTHER
Hoya Vision Care
CollaboratorINDUSTRY
University of Huddersfield
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 23 Years
Healthy volunteers
No

Inclusion criteria

* Myopic students studying at university * Aged 18-23 years at the start of the study * Show evidence of axial length growth of at least 0.06mm prior to entry into Stage 2 of the study. * Have read the patient information sheet and be happy to sign the consent forms * Be willing to adhere to the visit schedule and wearing times described in the protocol * Agree to accept either the control or test lenses as assigned by the randomisation * Have BCVA of +0.10 LogMAR or better in each eye

Exclusion criteria

* Previous myopia control use (optical or pharmacological) * Amblyopia * Myopic Rx up to -10D * Astigmatism up to 4D * Anisometropia \<1.75D * Binocular Vision anomalies (such as tropia) * Taking medications that affect pupil size or accommodation * A known allergy to tropicamide

Design outcomes

Primary

MeasureTime frameDescription
Axial length24 monthsChange in axial length relative to baseline
Cycloplegic SER24 monthsChange in spherical equivalent cycloplegic autorefraction relative to baseline

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORNeema Ghorbani-Mojarrad, PhD

University of Bradford

PRINCIPAL_INVESTIGATORKathryn Webber, MOptom

University of Bradford

PRINCIPAL_INVESTIGATORSophie Coverdale, PhD

University of Bradford

PRINCIPAL_INVESTIGATORNiall Hynes, PhD

University of Huddersfield

PRINCIPAL_INVESTIGATORCheryl Hill

University of Bradford

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026